December 1, 2009. Members of the Patient and Consumer Coalition strongly urge you to keep strong comparative effectiveness research (CER) language in the Senate health care reform bill.
Read More »On Health Policy
NCHR Testimony at the FDA Public Hearing on Promotion of Medical Products via the Internet and Social Media
November 12, 2009. Those of us who are here know that our concerns are shared by many other public health, patient, and consumer organizations. However, most do not have the staff or resources to set aside two days of unscheduled time for a meeting, especially non-reimbursed time, and especially in the middle of the health care reform negotiations.
Read More »Letter to Dr. Margaret Hamburg, FDA Commissioner, Urging that Immediate Action Be Brought to Appropriately Regulate Tanning Devices
November 5, 2009. Members of the Patient and Consumer Coalition urge your immediate attention to appropriately regulate tanning devices. As you know, currently, tanning devices are Class I devices (the same as bandages), which is the U.S. Food and Drug Administration’s (FDA) lowest risk device class and does not require comprehensive safety data.
Read More »Letter to Principal Deputy Commissioner Sharfstein Expressing Concerns About the Food and Drug Administration Amendments Act (FDAAA)
October 6, 2009. In September 2007, the Food and Drug Administration Amendments Act (FDAAA) was signed into law.
Read More »NCHR Comment on “Statement of Policy: Testing of Component Parts With Respect to Section 108 of the Consumer Product Safety Improvement Act”
September 16, 2009. Given that phthalate concentrations can be diluted in large toys, we agree with Commission staff that testing phthalate content as a percentage of the entire toy or child care article is less effective than testing materials and component parts that may contain phthalates.
Read More »